Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.

Michael E. Weinblatt, Joel Kremer, John Cush, William Rigby, Lichen L. Teng, Jenny Devenport, Natasha Singh, Denise Lepley, Mark C. Genovese

Research output: Contribution to journal › Article › peer-review